Top

Published in:

01-05-2019 | Langerhans Cell Histiocytosis | Original Article

Diverse cutaneous manifestation of Langerhans cell histiocytosis: a 10-year retrospective cohort study

Authors: Supattarawadee Poompuen, Jitjira Chaiyarit, Leelawadee Techasatian

Published in: European Journal of Pediatrics | Issue 5/2019

Abstract

Cutaneous manifestation is a common presentation of LCH and is usually a leading clue for the disease diagnosis. Having cutaneous lesions did not show a significantly early age onset at diagnosis compared to those without skin lesions, P value = 0.71. In the present study, cutaneous findings were found as 77.7%. Seborrheic dermatitis-like lesions were the most common cutaneous type (42.8%), followed by papules/nodules/masses (28.5%), petechiae/hemorrhagic lesions (17.8%), and eczematous lesions (10.7%). Time to diagnosis of LCH presented with seborrheic dermatitis-like lesions was significantly longer than other cutaneous presentations, P value = 0.0011.

Conclusion: Patients with LCH who had the manifestations of seborrheic dermatitis-like lesions can have diagnosis delayed due to the difficulty in distinguishing these lesions from normal seborrheic dermatitis lesions. Petechiae/hemorrhagic cutaneous signs in addition to the normal seborrheic dermatitis is the clue for early detection of the disease. To improve early detection of LCH, general pediatricians should be alerted to be aware of these skin symptoms, and if they persist, a dermatologist, pediatric if available, should be immediately consulted.

What is Known? • Cutaneous manifestation is a common presentation of LCH and is usually a leading clue for the disease diagnosis.
What is New? • Patients with LCH who have the manifestations of seborrheic dermatitis-like lesions can have a delayed diagnosis due to the difficulty in distinguishing normal from seborrheic dermatitis lesions. • Petechiae/hemorrhagic cutaneous signs in addition to the normal seborrheic dermatitis are the clue to the early disease detection.

Techasatian L, Waraasawapati S (2017) Multiple yellow-red papules on the head and neck in a 3-month-old boy. Pediatr Int Off J Jpn Pediatr Soc 59(1):118–119CrossRef

Mandel VD, Ferrari C, Cesinaro AM, Pellacani G, Del Forno C (2014) Congenital “self-healing” Langerhans cell histiocytosis (Hashimoto-Pritzker disease): a report of two cases with the same cutaneous manifestations but different clinical course. J Dermatol 41(12):1098–1101CrossRefPubMed

Wollina U, Langner D, Hansel G, Schönlebe J (2016) Cutaneous Langerhans cell histiocytosis: the spectrum of a rare cutaneous neoplasia. Wien Med Wochenschr 1946:5

Ng SS-Y, Koh MJ-A, Tay Y-K (2013) Cutaneous Langerhans cell histiocytosis: study of Asian children shows good overall prognosis. Acta Paediatr Oslo Nor 1992 102(11):e514–e518

Morren M-A, Vanden Broecke K, Vangeebergen L, Sillevis-Smitt JH, Van Den Berghe P, Hauben E et al (2016) Diverse cutaneous presentations of Langerhans cell histiocytosis in children: a retrospective cohort study. Pediatr Blood Cancer 63(3):486–492CrossRef

Minkov M, Prosch H, Steiner M, Grois N, Pötschger U, Kaatsch P et al (2005) Langerhans cell histiocytosis in neonates. Pediatr Blood Cancer 45(6):802–807CrossRefPubMed

Flores-Terry MA, Sanz-Trenado JL, García-Arpa M, Cortina-de la Calle MP (2018) Cutaneous Langerhans cell histiocytosis presenting in adulthood. Actas Dermosifiliogr

Allen CE, Merad M, McClain KL (2018) Langerhans-cell histiocytosis. N Engl J Med 379(9):856–868CrossRefPubMed

Tran G, Huynh TN, Paller AS (2018) Langerhans cell histiocytosis: a neoplastic disorder driven by Ras-ERK pathway mutations. J Am Acad Dermatol 78(3):579–590.e4CrossRefPubMed

10.

Chong VC-L, Tan CL, Chee Y-L, De Mel S (2018) A young patient with a lytic skull lesion. J Clin Pathol 26

11.

Zhu H, Ma Y, Sun L, Zhang R, Lv L, Wang A (2018) Langerhans cell histiocytosis with lymph node involvment presenting as erythroderma. Acta Derm Venereol

12.

Stein SL, Paller AS, Haut PR, Mancini AJ (2001) Langerhans cell histiocytosis presenting in the neonatal period: a retrospective case series. Arch Pediatr Adolesc Med 155(7):778–783CrossRefPubMed

13.

El Fekih N, Kamoun I, Jones M, Remmeh S, Zéglaoui F, Ben Slama C et al (2013) Histiocytosis X revealed by diabetes insipidus and skin lesions. Am J Dermatopathol 35(5):606–608CrossRefPubMed

14.

Rigaud C, Barkaoui MA, Thomas C, Bertrand Y, Lambilliotte A, Miron J et al (2016) Langerhans cell histiocytosis: therapeutic strategy and outcome in a 30-year nationwide cohort of 1478 patients under 18 years of age. Br J Haematol 174(6):887–898CrossRef

15.

Ahuja A, Uppe A, Nair G (2018) Multisystem involvement of Langerhans cell histiocytosis. J Assoc Physicians India 66(4):75–76PubMed

16.

Favara BE, Feller AC, Pauli M, Jaffe ES, Weiss LM, Arico M et al (1997) Contemporary classification of histiocytic disorders. The WHO Committee On Histiocytic/Reticulum Cell Proliferations Reclassification Working Group of the Histiocyte Society. Med Pediatr Oncol 29(3):157–166CrossRef

17.

Behera B, Malathi M, Thappa DM, Gochhait D, Srinivas BH, Toi PC (2018) Dermoscopic features of three cases of Langerhans cell histiocytosis. Indian J Dermatol Venereol Leprol 84(6):730–735CrossRefPubMed

18.

Krooks J, Minkov M, Weatherall AG (2018) Langerhans cell histiocytosis in children: Diagnosis, differential diagnosis, treatment, sequelae, and standardized follow-up. J Am Acad Dermatol 78(6):1047–1056CrossRefPubMed

19.

Bellinato F, Maurelli M, Colato C, Balter R, Girolomoni G, Schena D (2018) BRAF V600E expression in juvenile xanthogranuloma occurring after Langerhans cell histiocytosis. Br J Dermatol

20.

Varga E, Korom I, Polyánka H, Szabó K, Széll M, Baltás E et al (2015) BRAFV600E mutation in cutaneous lesions of patients with adult Langerhans cell histiocytosis. J Eur Acad Dermatol Venereol 29(6):1205–1211CrossRef

21.

Rizzo FM, Cives M, Simone V, Silvestris F (2014) New insights into the molecular pathogenesis of langerhans cell histiocytosis. Oncologist 19(2):151–163CrossRefPubMedPubMedCentral

22.

Chan MMH, Tan DJA, Koh MJ-A, Tan LS (2018) Blistering Langerhans cell histiocytosis. Lancet Oncol 19(9):e500CrossRefPubMed

23.

Dodd E, Hook K (2016) Topical Imiquimod for the treatment of childhood cutaneous Langerhans cell histiocytosis. Pediatr Dermatol 33(3):e184–e185CrossRefPubMed

Title: Diverse cutaneous manifestation of Langerhans cell histiocytosis: a 10-year retrospective cohort study
Authors: Supattarawadee Poompuen
Jitjira Chaiyarit
Leelawadee Techasatian
Publication date: 01-05-2019
Publisher: Springer Berlin Heidelberg
Keywords: Langerhans Cell Histiocytosis
Petechiae
Published in: European Journal of Pediatrics / Issue 5/2019
Print ISSN: 0340-6199
Electronic ISSN: 1432-1076
DOI: https://doi.org/10.1007/s00431-019-03356-1

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Diverse cutaneous manifestation of Langerhans cell histiocytosis: a 10-year retrospective cohort study

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2019

Magnetic resonance imaging characteristics of injection site reactions after long-term subcutaneous delivery of drisapersen

Humanization interventions in general pediatric wards: a systematic review

Adrenal crises in children with adrenal insufficiency: epidemiology and risk factors

How can we provide true synchronization in synchronized NIPPV?

NTproBNP is a useful early biomarker of bronchopulmonary dysplasia in very low birth weight infants

Skeletal disproportion in glucocorticoid-treated boys with Duchenne muscular dystrophy